Also known as FPF-1070 · porcine brain-derived peptide preparation
A porcine-brain-derived mixture of neuropeptides and free amino acids with neurotrophic activity — approved for stroke and dementia outside the US.
Research refreshed
Cerebrolysin is not a single molecule but a standardized mixture — low-molecular-weight neuropeptides (about 15%) and free amino acids (about 85%) produced by enzymatic breakdown of purified pig-brain proteins. Its small peptide fraction is able to cross the blood–brain barrier, where it is studied for mimicking the brain’s own neurotrophic factors. It is one of the most widely used injectable nootropics in the world, approved in dozens of countries for stroke, traumatic brain injury, and dementia — though not by the FDA.
Cerebrolysin belongs to a small group of entries in this catalog that are not single peptides at all but defined biological mixtures — like the glycoprotein hormones, it cannot be captured by one molecular formula. It is manufactured by EVER Pharma (originally EBEWE, Austria) from purified porcine brain proteins broken down by controlled enzymatic hydrolysis, yielding a reproducible blend of short neuropeptides and free amino acids standardized by peptide-nitrogen content rather than by a sequence.
The rationale is neurotrophic mimicry: the low-molecular-weight peptide fraction is small enough to cross the blood–brain barrier and is proposed to reproduce, in part, the actions of the brain’s own growth factors — BDNF, NGF, GDNF and others — that support neuron survival and synapse formation. It has one of the largest clinical literatures of any nootropic, spanning ischemic stroke, traumatic brain injury, vascular dementia, and Alzheimer’s disease, and is approved in roughly 44 countries across Europe and Asia. It is not FDA-approved in the United States, where it is imported and used off-label.
Neurotrophic and neuroprotective activity attributed to peptide fragments that mimic endogenous neurotrophic factors (BDNF, NGF, GDNF, CNTF), supporting neuronal survival, neuroplasticity, and synaptogenesis.
Behind every vial of Cerebrolysin is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Cerebrolysin, specifically, is brought into being.
Cerebrolysin begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Cerebrolysin is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — Cerebrolysin plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Cerebrolysin proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Cerebrolysin — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Cerebrolysin is not synthesized but manufactured from purified porcine brain protein by controlled enzymatic hydrolysis, then standardized — its potency is defined by peptide-nitrogen content and a consistent low-molecular-weight profile, not by a single sequence or purity number. Because it is a biological mixture, quality rests on batch-to-batch reproducibility, species-source control, and freedom from larger proteins, closer to a biologic than to a synthetic peptide.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Cerebrolysin, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Cerebrolysin is a standardized mixture of small neuropeptides and free amino acids made from purified porcine brain proteins, studied for neurotrophic and neuroprotective effects in stroke, brain injury, and dementia.
No — it is a defined biological mixture (about 15% low-molecular-weight peptides and 85% free amino acids), so it has no single sequence or molecular formula.
No. It is approved in roughly 44 countries across Europe and Asia for stroke, traumatic brain injury, and dementia, but it is not FDA-approved in the United States. This page is a research and educational reference.
Its small peptides can cross the blood–brain barrier and are proposed to mimic the brain’s own neurotrophic factors (BDNF, NGF, GDNF), supporting neuron survival and synapse formation.
Dosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.